This site is intended for healthcare professionals
Drug information

Flucloxacillin

POM
Read time: 10 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications

Treatment of infections due to sensitive Gram-positive organisms, including infections caused by β-lactamase-producing Staphylococci and Streptococci.

Typical indications include:

Skin and soft tissue infections:

Boils

Impetigo

Abscesses

Infected wounds

Carbuncles

Infected burns

Furunculosis

Protection for skin grafts

Cellulitis

Infected skin conditions e.g. ulcers, eczema and acne.

Respiratory tract infections:

Pneumonia

Pharyngitis

Lung abscess

Tonsillitis

Empyema

Quinsy

Sinusitis

Otitis media and externa

Other infections caused by flucloxacillin-sensitive organisms:

Osteomyelitis

Septicaemia

Enteritis

Meningitis

Endocarditis

Urinary-tract infection

Flucloxacillin is also indicated for use as a prophylactic during major surgical procedures such as cardiothoracic and orthopaedic surgery. Parenteral usage is indicated where oral dosage is inappropriate.

Consideration should be given to official local guidance (e.g. national recommendations) on the appropriate use of antibacterial agents.

Susceptibility of the causative organism to the treatment should be tested (if possible), although therapy may be initiated before the results are available.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).